1. Deregulated expression of VHL mRNA variants in papillary thyroid cancer
- Author
-
Francesco Tartaglia, Poupak Fallahi, Corrado De Vito, Marco Bononi, Antonio Catania, Yannick Arlot-Bonnemains, Enke Baldini, Salvatore Sorrenti, Alessandro Antonelli, Susi Barollo, Angelo Filippini, Frank Chesnel, Massimo Vergine, Stefano Arceri, Eleonora D'Armiento, Domenico Mascagni, Caterina Mian, Salvatore Ulisse, Chiara Tuccilli, Massimo Monti, Sara Watutantrige-Fernando, Daniele Pironi, Department of Surgical Sciences, Università degli Studi di Roma 'La Sapienza' = Sapienza University [Rome], Department of Experimental Medicine, Institut de Génétique et Développement de Rennes (IGDR), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Centre National de la Recherche Scientifique (CNRS)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Department of Internal Medicine, University of Pisa - Università di Pisa, Department of Medical and Surgical Sciences, Universita degli Studi di Padova, Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )-Centre National de la Recherche Scientifique (CNRS)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES), Università degli Studi di Roma 'La Sapienza' = Sapienza University [Rome] (UNIROMA), Université de Rennes (UR)-Centre National de la Recherche Scientifique (CNRS)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), and Università degli Studi di Padova = University of Padua (Unipd)
- Subjects
Male ,0301 basic medicine ,Biomarkers ,gene expression ,papillary thyroid cancer ,prognosis ,VHL ,biochemistry ,Molecular Biology ,Endocrinology ,endocrine system diseases ,Papillary thyroid cancer ,Kaplan-Meier Estimate ,Biochemistry ,0302 clinical medicine ,Gene expression ,Child ,Lymph node ,Aged, 80 and over ,Univariate analysis ,Thyroid ,Middle Aged ,Prognosis ,Gene Expression Regulation, Neoplastic ,medicine.anatomical_structure ,Thyroid Cancer, Papillary ,Von Hippel-Lindau Tumor Suppressor Protein ,030220 oncology & carcinogenesis ,Female ,Adult ,Proto-Oncogene Proteins B-raf ,medicine.medical_specialty ,Adolescent ,Tumor suppressor gene ,Matched Tissues ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,Biology ,Disease-Free Survival ,Young Adult ,03 medical and health sciences ,Internal medicine ,medicine ,Humans ,RNA, Messenger ,Thyroid Neoplasms ,Aged ,[SDV.GEN]Life Sciences [q-bio]/Genetics ,Histology ,medicine.disease ,Carcinoma, Papillary ,Alternative Splicing ,030104 developmental biology ,Mutation ,Cancer research - Abstract
International audience; Recent findings demonstrated that a subset of papillary thyroid cancers (PTCs) is characterized by reduced expression of the von Hippel-Lindau (VHL) tumor suppressor gene, and that lowest levels associated with more aggressive PTCs. In the present study, the levels of the two VHL mRNA splicing variants, VHL-213 (V1) and VHL-172 (V2), were measured in a series of 96 PTC and corresponding normal matched tissues by means of quantitative RT-PCR. Variations in the mRNA levels were correlated with patients' clinicopathological parameters and disease-free interval (DFI). The analysis of VHL mRNA in tumor tissues, compared to normal matched tissues, revealed that its expression was either up- or down-regulated in the majority of PTC. In particular, V1 and V2 mRNA levels were altered, respectively, in 78 (81.3%) and 65 (67.7%) out of the 96 PTCs analyzed. A significant positive correlation between the two mRNA variants was observed (p
- Published
- 2017
- Full Text
- View/download PDF